Cancer vaccines: will we ever learn?

  title={Cancer vaccines: will we ever learn?},
  author={Robert Johnson and Anthony Walker and Stephen Ward},
  journal={Expert Review of Anticancer Therapy},
  pages={67 - 74}
Scientists and clinicians engaged in developing therapeutic cancer vaccines cannot be anything other than troubled by the sheer number of Phase III clinical trial failures in the field. Are we inveterate optimists or do we have reason for continuing to plough our lonely furrow? In this perspective article, we answer why Phase III failures have been to the fore and highlight why the field should be optimistic given the knowledge gained from these pioneering studies and our improved understanding… 
Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy
By breaking immune inhibition and facilitating immune stimulation, immune regulatory antibodies show great promise in the treatment of a variety of tumors.
Developments in anticancer vaccination: budding new adjuvants
The purpose of this review is to summarize the latest discoveries of TLR-synthetic agonists with adjuvant potential in anti-cancer vaccination.
Commercialization of cellular immunotherapies for cancer.
The promise of 'game-changing' efficacy, as exemplified by very high levels of complete responses in refractory haematological malignancies, has attracted capital investments on a vast scale, and the attendant pace of technology development provides promising indicators for future clinical and commercial success.
Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines.
Researchers have begun to explore the use of cancer vaccines in conjunction with HSCT, with exciting results.
Can calcium signaling be harnessed for cancer immunotherapy?
  • R. Rooke
  • Biology
    Biochimica et biophysica acta
  • 2014
Chimeric Antigen Receptor Therapy in Haematology and Oncology : Current Successes and Challenges Commercialization of cellular immunotherapies for cancer
Clinical trials have revealed spectacular efficacy in refractory leukaemia patients using anti-CD19 chimeric antigen receptor (CAR) adoptive T-cell therapy, and this and other data have ignited investor interest in the biotech sector and this field in particular.
Clinical Cancer esearch cer Therapy : Preclinical erior Efficacy of Tumor Cell Vaccines R wn in Physiologic Oxygen
Results have profound implications for cancer vaccines that utilize tumor cells as the source of antigen by functions as an “immunologic switch” by dictating the cellular and humoral immune responses elicited by tumor cell lysates.
Cancer vaccine strategies and studies of human thioredoxin reductase splice variants
It was demonstrated that vaccination of mice with β2m-deficient dendritic cells, prior to a challenge with a tumorigenic dose ofβ2mfree tumor cells of syngeneic origin, protected the vaccinated mice from tumor development, and cell-based and DNA vector-based cancer vaccine strategies were studied with the potential to be used in therapeutic cancer vaccine approaches.
Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.


What’s the (end) point of cancer vaccines?
Subgroup analyses across studies suggest that they have their greatest benefits when the tumor antigen load is low, and more weight should be given to subgroup analyses, particularly in the adjuvant setting where there is a strong mechanistic rationale for use of such therapies in addition to standard of care.
Cancer vaccines as a therapeutic strategy
The concept of cancer vaccines is as a therapeutic strategy to immunize the body against cancer antigens that may not be presented by the cancer itself, due to the marked immunosuppressive effects of
Active Specific Immunotherapy with Autologous Tumor cell vaccines for Stage II Colon Cancer: Logistics, Efficacy, Safety and Immunological Pharmacodynamics
This commentary describes the “trials and tribulations” of developing a patient specific, autologous tumor cell vaccine for therapy of Stage II colon cancer.
Experimental systems and clinical practices: Tumor immunology and cancer immunotherapy, 1895–1980
  • I. Löwy
  • Medicine
    Journal of the history of biology
  • 1994
Au debut du XX e siecle, on pensait traiter les cancers par vaccination, en inoculant un serum prepare contre the tumeur, but le fallut attendre l'alliance de l'immunologie and de the medecine clinique oncologique en 1970 pour developper l'IMmunotherapie des cancers.
Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL)
LB-204 Abstract LB-140 was submitted as a Late-Breaking Abstract and is embargoed until the time of presentation. The complete abstract will be posted to this site at or after the following date and
Allogeneic whole‐cell vaccine: a phase I/II study in men with hormone‐refractory prostate cancer
Objective To establish the safety and toxicity of an allogeneic human tumour cell vaccine in patients with hormone‐refractory prostate cancer, and to determine any biochemical, immunological or
Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors
The two-step strategy of tumor immunotherapy that is presented is based on the rationale that it is necessary to eliminate or ameliorate the immunological eclipse as a precondition to allow an otherwise ineffective anti-tumor immunological therapy to have a chance to be successful.
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.
It is shown that MUC1 peptide-pulsed dendritic cells can induce clinical and immunologic responses in patients with metastatic RCC, and in patients responding to the treatment, T-cell responses to antigens not used for vaccinations could be detected, indicating that epitope spreading might occur.
Would oncologists want chemotherapy if they had non-small-cell lung cancer?
A new survey of oncologists attending a 1997 National Comprehensive Cancer Network annual meeting found that only about one-third of physicians and oncology nurses would have consented to chemotherapy for non-small-cell lung cancer in 1985.